Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

This degree of success can become a double-edged sword, though. While the drug has thrived since its first approval back in ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

Merck’s MRK stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early November, indicating sustained bullish momentum. The 50-day moving average is a short-term ...

A German court has ordered Merck & Co (NYSE: MRK) to halt launch preparations for its new subcutaneous version of Keytruda ...

Two leading medical stocks that appear reasonable at current levels are AbbVie (NYSE: ABBV) and Merck (NYSE: MRK). The former ...

Zydus will commercialise FYB206 in North America, while Formycon will lead development, regulatory filings and supply, with a ...

Preoperative radiation improved T-cell infiltration among patients with hormone receptor-positive, HER2-negative breast ...

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...

Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...